{"prompt": "['The VWD Minimize Menorrhagia (VWDMin) Trial', 'VWDMin', 'Short Title: The VWDMin Trial', 'Protocol Number: PRO15070638', 'Coordinating Center Protocol Number: PRO17070582', 'National Clinical Trial (NCT) Identified Number: NCT02606045', 'Principal Investigator: Margaret V. Ragni, MD, MPH', 'Sponsor: Margaret V. Ragni, MD, MPH', 'Funded by: NHLBI', 'Version Number: v1.0', '19 March 2018', 'Summary of Changes from Previous Version:', 'Affected', 'Summary of Revisions Made', 'Rationale', 'Section(s)']['STATEMENT OF COMPLIANCE', '1', '1', 'PROTOCOL SUMMARY', '2', '1.1', 'Synopsis', '2', '1.2', 'Schema', '4', '1.3', 'Schedule of Activities (SoA)', '5', '2', 'INTRODUCTION', '5', '2.1', 'Study Rationale', '5', '2.2', 'Background', '6', '2.3', 'Risk/Benefit Assessment', '9', '2.3.1', 'Known Potential Risks', '9', '2.3.2', 'Known Potential Benefits', '12', '2.3.3', 'Assessment of Potential Risks and Benefits', '12', '3', 'OBJECTIVES AND ENDPOINTS', '13', '4', 'STUDY DESIGN', '13', '4.1', 'Overall Design', '13', '4.2', 'Scientific Rationale for Study Design', '14', '4.3', 'Justification for Dose', '14', '4.4', 'End of Study Definition', '15', '5', 'STUDY POPULATION', '15', '5.1', 'Inclusion Criteria', '15', '5.2', 'Exclusion Criteria', '15', '5.3', 'Screen Failures', '16', '5.4', 'Strategies for Recruitment and Retention', '16', '6', 'STUDY INTERVENTION', '17', '6.1', 'Study Intervention(s) Administration', '17', '6.1.1', 'Study Intervention Description', '17', '6.1.2', 'Dosing and Administration', '18', '6.2', 'reparation/Handling/Storage/Accountability', '19', '6.2.1', 'Acquisition and accountability', '19', '6.2.2', 'Formulation, Appearance, Packaging, and Labeling', '19', '6.2.3', 'Product Storage and Stability', '19', '6.2.4', 'Preparation', '20', '6.3', 'Measures to Minimize Bias: Randomization and Blinding', '20', '6.4', 'Study Intervention Compliance', '21', '6.5', 'Concomitant Therapy', '21', '6.5.1', 'Rescue Medicine', '21', '7', 'STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT', 'DISCONTINUATION/WITHDRAWAL', '21', '7.1', 'Discontinuation of Study Intervention', '21', '7.2', 'Participant Discontinuation/Withdrawal from the Study', '22', '7.3', 'Lost to Follow-Up', '23', '8', 'STUDY ASSESSMENTS AND PROCEDURES', '23', '8.1', 'Efficacy Assessments', '23', '8.2', 'Safety and Other Assessments', '25', '8.3', 'Adverse Events and Serious Adverse Events', '26', '8.3.1', 'Definition of Adverse Events (AE)', '26', '8.3.2', 'Definition of Serious Adverse Events (SAE)', '26', '8.3.3', 'Classification of an Adverse Event', '27']['8.3.4', 'Time Period and Frequency for Event Assessment and Follow-Up', '29', '8.3.5', 'Adverse Event Reporting', '29', '8.3.6', 'Serious Adverse Event Reporting', '30', '8.3.7', 'Reporting Events to Participants', '30', '8.3.8', 'Events of Special Interest', '30', '8.3.9', 'Reporting of Pregnancy', '30', '8.4', 'Unanticipated Problems', '30', '8.4.1', 'Definition of Unanticipated Problems (UP)', '30', '8.4.2', 'Unanticipated Problem Reporting', '31', '8.4.3', 'Reporting Unanticipated Problems to Participants', '31', '9', 'STATISTICAL CONSIDERATIONS', '31', '9.1', 'Statistical Hypotheses', '31', '9.2', 'Sample Size Determination', '32', '9.3', 'Populations for Analyses', '33', '9.4', 'Statistical Analyses', '33', '9.4.1', 'General Approach', '33', '9.4.2', 'Analysis of the Primary Efficacy Endpoint(s)', '33', '9.4.3', 'Analysis of the Secondary Endpoint(s)', '34', '9.4.4', 'Safety Analyses', '34', '9.4.5', 'Baseline Descriptive Statistics', '35', '9.4.6', 'Planned Interim Analyses', '35', '9.4.7', 'Sub-Group Analyses', '35', '9.4.8', 'Tabulation of Individual participant Data', '35', '9.4.9', 'Exploratory Analyses', '35', '10', 'SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS', '37', '10.1', 'Regulatory, Ethical, and Study Oversight Consideration', '37', '10.1.1', 'Informed Consent Process', '37', '10.1.2', 'Study Discontinuation and Closure', '37', '10.1.3', 'Confidentiality and Privacy', '38', '10.1.4', 'Future Use of Stored Specimens and Data', '39', '10.1.5', 'Key Roles and Study Governance', '40', '10.1.6', 'Safety Oversight', '40', '10.1.7', 'Clinical Monitoring', '41', '10.1.8', 'Quality Assurance and Quality Control', '44', '10.1.9', 'Data Handling and Record Keeping', '45', '10.1.10', 'Protocol Deviations', '46', '10.1.11', 'Publication and Data Sharing Policy', '46', '10.1.12', 'Conflict of Interest Policy', '47', '10.2', 'Additional Considerations', '47', '10.2.1', 'Costs and Payments', '47', '10.2.2', 'Human Subjects', '48', '10.2.3', 'Qualifications', '48', '10.3', 'Abbreviations', '50', '10.4', 'Protocol Amendment History', '51', '11', 'REFERENCES', '52']\n\n###\n\n", "completion": "END"}